VIII. 10 Chemotherapy

Chemotherapy targets fast-dividing tumor cells, but it also bruises the equally fast-renewing gut lining and microbiota – so protecting your gut flora is part of supportive care.

Chemotherapy – Collateral Damage to Microbial Ecosystems

Chemotherapy targets rapidly dividing cancer cells but also harms beneficial gut microbes, leading to profound dysbiosis [628].

The origins of cancer chemotherapy lie not in an oncology ward but in a wartime chemical weapons programme. During the Second World War, pharmacologists Alfred Gilman and Louis Goodman at Yale University were recruited by the US Army to investigate the therapeutic potential of nitrogen mustard compounds – derivatives of the mustard gas used as a weapon in the First World War. Autopsies of soldiers exposed to mustard gas had shown a striking finding: profound suppression of bone marrow and lymphoid tissue. Gilman and Goodman reasoned that a compound capable of destroying rapidly dividing immune cells might also destroy lymphoma. In December 1942, they treated their first patient – a man with advanced lymphosarcoma whose tumour had stopped responding to radiation – with intravenous nitrogen mustard. The tumour regressed dramatically, though the response was temporary. The work was classified as a military secret until 1946. When it was published, it marked the beginning of modern chemotherapy. The logic has not changed: find a compound that kills cells that divide rapidly. The problem, present from the very first patient, has also not changed: the gut epithelium renews itself every three to five days. It has always been among the fastest-dividing tissues in the body, and it has always been in the path of any agent designed to stop rapid division. The microbiota that inhabits it has no protection that chemotherapy recognises.

The intersection of cancer chemotherapy and gut microbiota entered clinical relevance through two converging research fronts. The first was the recognition that chemotherapy-associated gastrointestinal toxicity – mucositis, diarrhea, and infection vulnerability – showed unexplained patient-to-patient variability that baseline microbiota composition partially predicted. [628] The second was the discovery that gut microbiota influences the efficacy of cancer immunotherapy. [176] A pivotal study by Routy and colleagues published in Science in 2018 examined patients with non-small-cell lung cancer and renal cell carcinoma receiving checkpoint inhibitor immunotherapy (anti-PD-1/PD-L1 therapy). Patients who had taken antibiotics in the two months before starting immunotherapy had significantly shorter progression-free and overall survival. Germ-free^[G] or antibiotic-treated mice showed impaired responses to checkpoint inhibitors, and the response was restored when specific bacteria – particularly Akkermansia muciniphila – were reintroduced. Faecal transplantation from immunotherapy responders to non-responders improved response in some cases. [176] The mechanism involves the gut microbiota's role in priming systemic immune responses. Certain gut bacteria promote the differentiation of specific T cell populations – including Th1 cells and CD8+ cytotoxic T cells – that are the primary effectors of checkpoint inhibitor activity. A microbiota depleted of these immunostimulatory taxa produces a less immunologically primed state that responds poorly to therapies designed to unleash existing immune activity. [111] For conventional chemotherapy, the mechanism is different: cytotoxic drugs damage rapidly dividing intestinal epithelial cells, disrupting the mucosal barrier and reducing the ecological diversity of the gut. Microbiota support during chemotherapy – primarily through dietary fiber and, in selected contexts, probiotics with documented mucosal-protective effects – is increasingly incorporated into oncology care protocols at specialist centers.

Chemotherapy is designed to injure rapidly dividing cancer cells, but it also affects other tissues that renew quickly–most notably the intestinal lining. Because the gut microbiota lives in close contact with this barrier, treatment often leads to dysbiosis, meaning a measurable shift in microbial balance and function. This matters clinically, because the microbiota contributes to digestion, immune signaling, and resistance to colonization by opportunistic organisms [111].

A key driver of symptoms is chemotherapy-induced mucositis, an inflammatory injury of the gastrointestinal mucosa. When the mucosal surface is damaged, the barrier becomes less effective and intestinal permeability can rise. Patients may experience pain, diarrhea, and difficulty maintaining nutrition and hydration–problems that can directly affect daily functioning and the ability to tolerate ongoing treatment.

Barrier injury also increases the likelihood that microbial products, and in some settings microbes themselves, cross the mucosa and stimulate immune responses. Clinically, this is relevant because it can contribute to fever, inflammation, and infection risk, especially in patients with neutropenia. The most precise way to describe this is not that it happens uniformly to everyone, but that chemotherapy creates conditions that can facilitate microbial translocation and inflammatory signaling in vulnerable patients.

Different drug classes have different microbiota effects. Agents such as 5-fluorouracil, cyclophosphamide, and platinum compounds have been linked–most consistently in preclinical models and increasingly in clinical observations–to changes in microbial diversity and composition. Rather than a single universal “signature,” the pattern varies with the regimen, the cancer type, baseline microbiota, diet, hospitalization, and especially concurrent antibiotics.

Because infections are a real concern during chemotherapy, antibiotics are sometimes necessary. However, antibiotics can further disrupt microbial communities and may worsen gastrointestinal symptoms in some patients. This is why many oncology teams aim for careful antimicrobial stewardship: treating infections promptly when needed, while avoiding unnecessary exposure that could deepen dysbiosis.

There is also a broader therapeutic implication. The microbiota can modulate immune tone and inflammatory pathways that influence how patients respond to treatment. In several preclinical settings, altering the microbiota changes both toxicity profiles and antitumor effects. In clinical practice, this does not translate into a one-size-fits-all rule, but it does support a more careful view of factors that disturb the microbiota during treatment.

From a practical standpoint, the safest goal is to support the gut barrier and symptom control. Patients often do best with simple, well-tolerated foods, adequate protein and calories, and steady hydration. The usefulness of fermented foods or probiotics depends on the individual situation; in patients with severe mucositis, profound immunosuppression, or central lines, these choices should be discussed with the oncology team before use.

Chemotherapy remains essential in many cancers, but it is not biologically “local.” It can affect the gut barrier and the microbial ecosystem that supports it, contributing to gastrointestinal symptoms and infection vulnerability. A clinically realistic, evidence-aligned message is that dysbiosis is common, patterns vary, and supportive care should focus on barrier protection, symptom management, and safety during periods of immunosuppression.

How to Support the Microbiota During Chemotherapy

Support for the microbiota is best viewed as part of overall supportive care rather than as a separate therapy. Nutritional approaches that are gentle on the gut, provide adequate protein and energy, and include natural sources of fermentable fibers can help maintain baseline resilience during treatment.

Protection of the mucosal barrier is a central goal. Clinicians often consider strategies that reduce irritation of the intestinal lining, ensure sufficient hydration, and, when appropriate, use medically supervised enteral nutrition or specific nutrients that may aid epithelial recovery.

Antimicrobial use requires careful balance. While antibiotics are sometimes lifesaving during chemotherapy, unnecessary or prolonged courses can deepen microbial disruption, so therapeutic decisions ideally weigh infection control against preservation of microbial stability.

After completion of treatment, attention shifts toward gradual restoration. Dietary normalization, cautious reintroduction of fiber-rich foods, and avoidance of additional mucosal stressors can support the natural recovery of microbial communities; more intensive microbiota-directed interventions remain individualized and are not routine.

Close observation of gastrointestinal symptoms is essential. Early recognition and management of mucositis, diarrhea, or malnutrition not only improves comfort but may also limit secondary complications that further disturb the microbiota.

Microbiota Effects

• Chemotherapy is frequently associated with a reduction in microbial diversity and functional richness, including a decline in bacteria regarded as keystone species for mucosal integrity [176].
• Injury to the intestinal barrier can increase permeability, allowing the passage of microbial products such as lipopolysaccharides, which may amplify systemic inflammatory signaling [629].
• The altered microbial environment may create favorable conditions for opportunistic organisms, including Enterococcus species and, in certain clinical situations, Clostridioides difficile (formerly Clostridium difficile).
• Disruption of host–microbiota interactions can modify immune regulation, potentially influencing the tolerability of chemotherapy and the intensity of gastrointestinal side effects.
• Restoration of the microbiota after treatment is often gradual and highly individual, and in some patients remains incomplete without careful nutritional support and prudent antimicrobial use.

Patient Guidance

• Try to keep meals simple and gut-friendly during treatment. Choose easily digestible foods that provide enough calories and protein to maintain strength.
• Do not start any probiotic or supplement without discussing it with your oncology team. Some products may be unsafe during neutropenia or severe mucositis.
• Use antibiotics only when clearly indicated. If they are necessary, take them as prescribed and inform your doctor about any new bowel symptoms.
• During mucositis or diarrhea, switch temporarily to low-residue, non-irritating foods, and reintroduce fibers gradually as symptoms improve.
• Drink fluids regularly throughout the day to support mucosal healing and prevent dehydration.
• Move gently every day, as you are able. Short walks can help bowel motility and overall well-being.
• Pay attention to early warning signs such as persistent diarrhea, abdominal pain, or weight loss, and report them promptly.
• Protect your gut after treatment ends by slowly rebuilding a varied diet rather than making sudden drastic changes.
• Remember that microbiota recovery takes time. Improvement usually happens over weeks to months, not days.

Key Evidence: Microbiome and Immune Checkpoint Inhibitor Response

The composition of the gut microbiome is associated with the response to immune checkpoint inhibitor (anti-PD-1) therapy: in melanoma, a favourable response was linked to a greater abundance of Faecalibacterium and Ruminococcaceae [629], while in epithelial tumours the presence of Akkermansia muciniphila separated responders from non-responders [176]. Whether this association can be reversed was tested by two phase 1 studies published in Science in 2021: combining faecal microbiota transplantation (FMT) from responder donors with anti-PD-1 therapy in anti-PD-1-refractory melanoma achieved a clinical response in 3 of 10 patients [750] and in 6 of 15 patients [192]. These are small, early-phase, single-arm studies without a control group – not phase 3 evidence, and outside melanoma the approach is unproven. Clinical message: the effectiveness of tumour immunotherapy is in part microbiome-mediated, so avoiding unnecessary antibiotic exposure before and during treatment is currently the best-supported practical conclusion.

References

[111] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link

Mechanistic review of short-chain fatty acids (SCFAs), produced by bacterial fermentation of dietary fibre. Fermentable fibre is the primary energy source for the colonic microbiota; the main fermentation products are **acetate, propionate and butyrate**. **Butyrate is the principal energy substrate of colonocytes**; SCFAs also influence barrier integrity, immune function and, once in the circulation, host metabolism, partly via G-protein-coupled receptors (GPR41/43) and histone deacetylase inhibition. This entry is the source for the textbook-level claims of III.2 (S-0302-01, -02). Important: a **review**, not original experimental data.

[176] Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018. Link

This translational study showed that primary resistance to PD-1/PD-L1 immune checkpoint inhibitors (ICIs) in advanced cancer can be attributed to abnormal gut microbiome composition, with antibiotics reducing ICI clinical benefit. FMT from ICI responders into germ-free or antibiotic-treated mice restored PD-1 blockade efficacy; nonresponder FMT did not. Stool metagenomics correlated ICI response with Akkermansia muciniphila abundance. Oral A. muciniphila after nonresponder FMT restored PD-1 efficacy via IL-12-dependent CCR9+CXCR3+CD4+ T-cell recruitment. The findings establish microbiome modulation as an adjunct to cancer immunotherapy.

[192] Davar D, Dzutsev AK, McCulloch JA et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021. Link

A clinical trial evaluated responder-derived FMT combined with anti-PD-1 in PD-1-refractory melanoma patients. The combination was well tolerated, provided clinical benefit in 6 of 15 patients, and induced rapid, durable microbiota perturbation. Responders showed increased abundance of taxa previously linked to anti-PD-1 response, increased CD8+ T-cell activation, and decreased IL-8-expressing myeloid cells. Distinct proteomic and metabolomic signatures, plus transkingdom network analyses, confirmed gut microbiome regulation of these immune changes. FMT can overcome resistance to PD-1 blockade in melanoma.

[628] Oh B, Boyle F, Pavlakis N, et al. Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. . 2021. Link

Clinical review of the bidirectional relationship between chemotherapy and the gut microbiome: cytotoxic agents induce dysbiosis, mucosal barrier damage and inflammation, contributing to gastrointestinal toxicity and adverse events.

[629] Gopalakrishnan V, Spencer CN, Nezi L et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018. Link

This study analyzed oral and gut microbiomes of 112 melanoma patients receiving anti-PD-1 therapy. Faecal microbiome analysis (n=43; 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P<0.01) and Ruminococcaceae abundance (P<0.01) in responders. Metagenomics revealed enriched anabolic pathways in responders' microbiota. Immune profiling indicated enhanced systemic and antitumor immunity in responders, replicated in germ-free mice receiving responder faecal transplants. The findings identify a favourable gut microbiome signature predictive of anti-PD-1 response in melanoma.

[750] Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021. Link

Baruch et al.'s 2021 Science paper is a phase 1 clinical trial assessing the safety and feasibility of faecal microbiota transplantation (FMT) from responder donors followed by reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma. Clinical responses were observed in three patients (two partial responses and one complete response), and the procedure was well tolerated. FMT was associated with favourable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumour microenvironment. The trial is small, single-arm and early phase: hypothesis-generating evidence that modulating the gut microbiota can overcome immune-checkpoint-inhibitor resistance, not confirmed efficacy evidence.